- Home
- ZNTL vs REFI Comparison
ZNTL vs REFI Comparison
Compare ZNTL & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- REFI
- Stock Information
- Founded
- ZNTL 2014
- REFI 2021
- Country
- ZNTL United States
- REFI United States
- Employees
- ZNTL N/A
- REFI N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- ZNTL Health Care
- REFI Real Estate
- Exchange
- ZNTL Nasdaq
- REFI Nasdaq
- Market Cap
- ZNTL 238.2M
- REFI 306.1M
- IPO Year
- ZNTL 2020
- REFI 2021
- Fundamental
- Price
- ZNTL $3.12
- REFI $15.39
- Analyst Decision
- ZNTL Buy
- REFI Buy
- Analyst Count
- ZNTL 7
- REFI 2
- Target Price
- ZNTL $10.86
- REFI $20.00
- AVG Volume (30 Days)
- ZNTL 1.2M
- REFI 73.0K
- Earning Date
- ZNTL 11-04-2024
- REFI 11-07-2024
- Dividend Yield
- ZNTL N/A
- REFI 12.22%
- EPS Growth
- ZNTL N/A
- REFI N/A
- EPS
- ZNTL N/A
- REFI 1.97
- Revenue
- ZNTL $40,560,000.00
- REFI $55,186,946.00
- Revenue This Year
- ZNTL N/A
- REFI N/A
- Revenue Next Year
- ZNTL N/A
- REFI $4.51
- P/E Ratio
- ZNTL N/A
- REFI $7.81
- Revenue Growth
- ZNTL N/A
- REFI 5.63
- 52 Week Low
- ZNTL $2.83
- REFI $13.86
- 52 Week High
- ZNTL $18.24
- REFI $17.65
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- REFI 42.89
- Support Level
- ZNTL $2.92
- REFI $15.37
- Resistance Level
- ZNTL $3.23
- REFI $15.85
- Average True Range (ATR)
- ZNTL 0.17
- REFI 0.13
- MACD
- ZNTL 0.00
- REFI -0.00
- Stochastic Oscillator
- ZNTL 38.33
- REFI 22.22
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.